Hepatocellular Carcinoma

Phase II Irofulven Trial Begins in Liver Cancer Patients

Published in Hepatitis Weekly, October 16th, 2000

MGI Pharma, Inc. (MOGN), Minneapolis, Minnesota, has initiated a Phase II liver cancer trial with its anti-cancer compound, irofulven, to evaluate the safety and efficacy of irofulven in those patients.

The trial is being conducted at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Keith Stuart, Harvard Medical School, and Beth Israel Deaconess Medical Center in Boston, observed, "Hepatocellular carcinoma is one of the leading causes of worldwide cancer deaths, and yet there is no good chemotherapy treatment for this disease. We developed this trial because irofulven has a novel mechanism of action and has shown early signs of activity in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry